Ineffectiveness of pyridoxine (B6) to alter secretion of growth hormone and prolactin and absence of therapeutic effects on galactorrhea-amenorrhea syndromes.
The acute effect of pyridoxine (B6) on serum GH and PRL levels and its chronic effects on galactorrhea in nine subjects (group I, n=4, idiopathic galactorrhea with normal PRL levels and normal menses; Group II, n=5, galactorrhea-amenorrhea with increased PRL levels) have been studied. Pyridoxine did not acutely alter GH or PRL levels. There was no decrease in galactorrhea, no resumption of menses and no decrease in PRL following tow months of B6 therapy. In contrast, bromocriptine was effective in suppressing galactorrhea and restoring normal menses in group II subjects and remains the therapy of choice for this purpose.
D000568:Amenorrhea / Q000188:drug therapy*; D001971:Bromocriptine / Q000627:therapeutic use; D005260:Female; D005687:Galactorrhea / Q000188:drug therapy*; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D007775:Lactation Disorders / Q000188:drug therapy*; D008598:Menstruation / Q000187:drug effects; D011247:Pregnancy; D011388:Prolactin / Q000097:blood*; D011736:Pyridoxine / Q000627:therapeutic use*
D001971:Bromocriptine; D011388:Prolactin; D013006:Growth Hormone; D011736:Pyridoxine